全文获取类型
收费全文 | 965篇 |
免费 | 56篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 6篇 |
妇产科学 | 8篇 |
基础医学 | 144篇 |
口腔科学 | 10篇 |
临床医学 | 103篇 |
内科学 | 145篇 |
皮肤病学 | 32篇 |
神经病学 | 88篇 |
特种医学 | 57篇 |
外科学 | 93篇 |
综合类 | 32篇 |
一般理论 | 1篇 |
预防医学 | 23篇 |
眼科学 | 35篇 |
药学 | 149篇 |
中国医学 | 30篇 |
肿瘤学 | 98篇 |
出版年
2023年 | 7篇 |
2022年 | 11篇 |
2021年 | 29篇 |
2020年 | 4篇 |
2019年 | 14篇 |
2018年 | 22篇 |
2017年 | 15篇 |
2016年 | 21篇 |
2015年 | 38篇 |
2014年 | 28篇 |
2013年 | 28篇 |
2012年 | 62篇 |
2011年 | 68篇 |
2010年 | 50篇 |
2009年 | 46篇 |
2008年 | 54篇 |
2007年 | 69篇 |
2006年 | 56篇 |
2005年 | 52篇 |
2004年 | 48篇 |
2003年 | 44篇 |
2002年 | 49篇 |
2001年 | 30篇 |
2000年 | 32篇 |
1999年 | 24篇 |
1998年 | 20篇 |
1997年 | 27篇 |
1996年 | 15篇 |
1995年 | 15篇 |
1994年 | 12篇 |
1993年 | 10篇 |
1992年 | 6篇 |
1991年 | 12篇 |
1990年 | 4篇 |
1989年 | 11篇 |
1988年 | 7篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1976年 | 4篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1967年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有1073条查询结果,搜索用时 15 毫秒
21.
Alpha interferon is an immune modulator used in the treatment of hematologic malignancies and immunosuppressive diseases. While many of the clinical indications for interferon have been well described and are FDA-approved, a large number of clinical uses of interferon are being developed. This study evaluated the appropriateness, efficacy, and safety of interferon therapy at our institution from 1987 to 1991. Data were collected by chart review. Response rates of patients in this hospital were compared to those published in the literature. Twenty-six patients were prescribed alpha interferon. Ten patients (38%) demonstrated a partial response, the highest responses seen in Hairy cell leukemia (67%) and chronic myelogenous leukemia (57%). Response rates for each disease compared favorably to those predicted from the literature. Twelve patients (46%) demonstrated intolerance. Overall five patients (19%) remain on therapy. While interferon appears to be moderately effective in certain diseases, intolerance to interferon seems to be the major limiting factor to its clinical application. 相似文献
22.
Despite strong clinical data confirming the anticonvulsant efficacy of a ketogenic diet (KGD) in pediatric patients, corroborative experimental data in young animals are limited. In the present study, the effects of a KGD on flurothyl seizure susceptibility were examined in normal juvenile mice after a dietary duration of 3, 7, or 12 days, and in adult mice for 15 days. In all groups of KGD-treated mice, blood beta-hydroxybutyrate levels were significantly elevated over those measured in controls. The present KGD was anticonvulsant (i.e. delayed onset) against the first (clonic) flurothyl-induced seizure for juvenile mice treated for either 7 or 12 days, but not for juvenile mice and adult mice fed the diet for 3 and 15 days, respectively. While this KGD was not anticonvulsant against the second (tonic extension) seizure induced by flurothyl in any of the juvenile groups, it significantly delayed tonic extension in the adult group. In addition, juvenile mice fed a KGD exhibited a lower mortality rate following flurothyl-induced seizures compared to mice fed a standard diet. In our discussion of animal models of the KGD, we highlight the need to understand better the impact of important variables such as dietary composition, genetic background, and mode of seizure induction in the study of the KGD. 相似文献
23.
Black tea and mammary gland carcinogenesis by 7,12- dimethylbenz[a]anthracene in rats fed control or high fat diets 总被引:3,自引:1,他引:3
Epidemiological studies suggest that tea may reduce cancer risk, and in
laboratory rodents, chemopreventive effects of tea or purified extracts of
tea have been demonstrated in lung, gastrointestinal tract and skin. There
is some evidence of chemoprevention by tea in the mammary gland, but the
data are not conclusive. In order to evaluate more fully the possible
influence of black tea on 7,12-dimethylbenz[a]anthracene (DMBA)-induced
mammary gland tumors in the female S-D (Sprague-Dawley) rat, three large
studies were performed: experiment 1, tumorigenesis in rats fed AIN-76A
diet and given 25 mg/kg DMBA and 1.25 or 2.5% whole tea extract or water to
drink; experiment 2, tumorigenesis in rats given 15 mg/kg DMBA and the same
diet and fluids as in experiment 1; experiment 3, tumorigenesis in rats fed
control or HF (high fat, corn oil) diet and given 15 mg/kg DMBA and 2% tea
or water to drink. Tea was given throughout the experiment; DMBA was given
by gastric gavage at 8 weeks of age. There was no consistent effect of tea
on tumorigenesis in rats fed AIN-76A diet; there was, however, evidence in
experiment 3 of a reduction of tumorigenesis by tea in rats fed the HF
diet. In experiment 3, rats fed the HF diet and given water showed the
expected increase in tumor burden (number and weight) compared with rats
fed control diet. However, rats fed the HF diet and given 2% tea showed no
increase in tumor burden; their tumor burden was significantly lower than
in rats fed the HF diet and given water (P < 0.01) and was not different
from rats fed control diet and given water or tea. In addition, in
experiment 3, the number of malignant tumors per tumor- bearing rat was
increased by the HF diet in water-drinking rats (P < 0.01) but not in
tea-drinking rats. Therefore, it appears that tea partially blocked the
promotion of DMBA-induced mammary tumorigenesis by the HF diet.
相似文献
24.
Han JY; Kim HK; Choi BG; Moon H; Hong YS; Lee KS 《Japanese journal of clinical oncology》1998,28(12):749-753
BACKGROUND: Quality of life (QOL) assessment has emerged to measure and
quantify the balance between treatment benefit and toxicity, and has a
value in predicting response and overall survival in cancer patients.
METHODS: From July 1995 to February 1997, 38 symptomatic patients with
advanced non-small cell lung cancer (NSCLC) were treated with MIP
chemotherapy (mitomycin 6 mg/m2, ifosfamide 3000 mg/m2 and cisplatin 50
mg/m2 on day 1 every 3 weeks). Patients were assessed for QOL including
physical well-being, general symptoms and lung cancer-specific symptoms, as
well as objective response. RESULTS: The overall response rate was 38.9%
(14/36, all were partial response) and the median duration of response was
3.5 months [95% confidence interval (CI) 2.0-4.0]. The median duration of
overall survival was 7 months (95% CI 5.9-8.5). The overall improvement of
QOL was 58.3% with 21 patients feeling better on treatment. The toxicity of
chemotherapy was mild, mainly nausea/vomiting and minimal alopecia. Using
multiple clinical predictors of survival (age, histology, stage,
performance status), only change of QOL emerged significantly (P = 0.0007).
CONCLUSIONS: MIP had an endurable response and low toxicity profile, and
provided good QOL. Integral QOL data in our study provided the strong
prediction of survival in advanced NSCLC. Further experienced QOL study
will provide greatly enhanced outcome data in clinical trials.
相似文献
25.
PURPOSE: To describe the clinical spectrum of lamotrigine (LTG)-induced tics (an uncommon side effect) in children. METHODS: Retrospective analysis of patients from our hospital-based practice who developed tics while on LTG. Data obtained from medical records, interviews with parents, video-EEGs, and homemade videotapes. RESULTS: Three males and two females (range, 2.5-12 years; mean, 6.9 years) developed a movement disorder within the first 10 months of therapy (maintenance doses, 4-17 mg/kg/day). Four patients exhibited simple motor tics; one patient experienced mostly vocal (i.e., gasping sounds) tics. Laryngoscopic evaluation of one 2.5-year-old with repetitive gasping sounds was normal. In three cases, tics resolved completely within 1 month of drug cessation; tics recurred in two of these patients after reintroduction of LTG. A fourth patient experienced gradual improvement after stopping LTG over 4 months; the fifth patient's simple motor tics improved spontaneously with a reduction in medication. None of the patients had clinical features of a neurodegenerative disorder, and none met diagnostic criteria for Tourette syndrome. Two patients, however, had a diagnosis of acquired epileptic aphasia syndrome, and one patient had nonprogressive expressive and receptive language dysfunction. A fourth patient had global static encephalopathy, and the fifth patient had only attentional problems. In all patients, tics were not associated with ictal EEG changes. CONCLUSIONS: LTG may infrequently induce simple motor tics, vocal tics, or both. Patients with severe language dysfunction may be particularly susceptible to this uncommon side effect. Further studies are necessary to clarify the population at risk. 相似文献
26.
27.
28.
29.
Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function 总被引:4,自引:4,他引:4
Platelets from a patient with a mild inherited bleeding disorder and abnormal platelet aggregation and secretion show reduced generation of inositol 1,4,5-trisphosphate, mobilization of intracellular Ca2+, and phosphorylation of pleckstrin in response to several G protein mediated agonists, suggesting a possible defect at the level of phospholipase C (PLC) activation (see accompanying report). A procedure was developed that allows quantitation of platelet PLC isozymes. After fractionation of platelet extracts by high-performance liquid chromatography, 7 out of 10 known PLC isoforms were detected by immunoblot analysis. The amount of these isoforms in normal platelets decreased in the order PLC- gamma 2 > PLC-beta 2 > PLC-beta 3 > PLC-beta 1 > PLC-gamma 1 > PLC- delta 1 > PLC-beta 4. Compared with normal platelets, platelets from the patient contained approximately one-third the amount of PLC-beta 2, whereas PLC-beta 4 was increased threefold. These results suggest that the impaired platelet function in the patient in response to multiple G protein mediated agonists is attributable to a deficiency of PLC-beta 2. They document for the first time a specific PLC isozyme deficiency in human platelets and provide an unique opportunity to understand the role of different PLC isozymes in normal platelet function. 相似文献
30.